Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Pathological complete response rates post neoadjuvant chemotherapy in molecular subtypes of breast cancer

From: Luminal-B breast cancer and novel therapeutic targets

     Pathological complete response rate (%)
Author n Method of molecular classification Defining luminal B Luminal A Luminal B HER2-positive Basal-like
Esserman and colleagues [25] 144 Microarray Intrinsic gene set and hierarchical clustering (included some HER2+) -5 13 55 34
De Ronde and colleagues [26] 191 Microarray Intrinsic gene set and hierarchical clustering (included some HER2+) 7 7 44 44
Bhargava and colleagues [27] 359 IHC surrogate markers ER-, HER2- 2 1 33 30
Carey and colleagues [28] 107 IHC surrogate markers ER+, HER2+ 0 15 36 27
Rouzier and colleagues [29] 82 Microarray Intrinsic gene set and hierarchical clustering (included some HER2+) 7a 7a 45 45
  1. ER, estrogen receptor; IHC, immunohistochemistry. aIn Rouzier and colleagues [29], luminal-A and luminal-B subtypes were grouped together as the luminal subtype.